Zepbound Results: How Much Weight Can You Lose (and How Fast)?

If you're searching for "Zepbound before and after," you're really asking two honest questions: how much weight does it actually take off, and how long does that take? The most truthful answer doesn't come from transformation photos — it comes from the controlled trials, where thousands of people were weighed on a schedule. This page walks through what those trials show, dose by dose and week by week, and is equally clear about what they don't promise: a fixed number for any one person, or fast results.

A note up front: Zepbound is the FDA-approved brand of tirzepatide for chronic weight management (Mounjaro is the same molecule approved for type 2 diabetes), it is prescription-only, and every figure below comes from controlled trials of the brand product — not compounded vials, which aren't held to the same standards². We can't and won't show before/after photos, because individual photos prove nothing about what you should expect. Trial averages do.

The headline number: about 15–21% on average, over 72 weeks

The pivotal trial is SURMOUNT-1 — a 72-week, placebo-controlled phase 3 study in adults with obesity (or overweight plus a weight-related condition) without diabetes. It tested all three maintenance doses, and the average weight loss at 72 weeks was¹:

| Weekly maintenance dose | Mean weight loss at 72 weeks | |-------------------------|------------------------------| | 5 mg | about 15.0% | | 10 mg | about 19.5% | | 15 mg | about 20.9% | | Placebo | about 3.1% |

For someone starting at 100 kg (about 220 lb), 15% is roughly 15 kg (33 lb) and 21% is about 21 kg (46 lb). That's a large, clinically meaningful result — and notice the placebo group still lost about 3%, a reminder that some of any program's early loss comes from the lifestyle changes that go alongside the drug, not the drug alone¹. For a deeper look at which dose to aim for, see our most effective Zepbound dose guide.

Most people respond — but "how much" varies widely

Averages hide the spread. In SURMOUNT-1, the share of people who lost at least 5% of their body weight was 85%, 89%, and 91% at 5, 10, and 15 mg — so most people respond to some degree¹. But the bigger results were less universal: 50% of the 10 mg group and 57% of the 15 mg group reached at least 20% loss¹. Read the flip side honestly — roughly half of even the highest-dose group did not hit the 20% mark, and a minority lost little. A network meta-analysis confirms tirzepatide's higher doses sit at the top of the class for weight loss, but it too reports group-level estimates, not a personal guarantee⁴. So the honest framing of "how much will I lose" is a range, weighted toward a good result, not a single promised figure.

How fast: months, not weeks

This is where "before and after" expectations most often go wrong. Zepbound is deliberately slow to get going. The dose is started at 2.5 mg purely as a run-in and raised in 2.5 mg steps no closer than four weeks apart, so it takes around five months just to climb to a 15 mg maintenance dose². SURMOUNT-1 itself built in a 20-week dose-escalation period, and the headline numbers above are measured at 72 weeks — almost a year and a half¹.

What that means in practice: the weight-loss curve falls fastest in the first several months, then keeps declining more gradually, and in the trials it was still trending downward late in the study rather than having fully plateaued early¹. Early weeks on a low starting dose typically produce modest change; the bigger losses accrue over many months on a higher maintenance dose. Anyone expecting a dramatic drop in the first few weeks is measuring against the wrong timeline. A realistic mental model: think in quarters and years, not weeks. For how the side effects track that same titration schedule, see how long Zepbound side effects last.

Results depend on context — diabetes is the clearest example

The same drug produces different average results in different populations. SURMOUNT-2 ran tirzepatide in adults who had obesity and type 2 diabetes, and average loss was lower: about 12.8% at 10 mg and 14.7% at 15 mg over 72 weeks — several points below the ~20% seen without diabetes³. That's a well-documented pattern across the weight-loss-drug class, and it's a concrete illustration that your starting health, not just your dose, shapes the number. Your baseline weight, adherence, and the lifestyle changes you pair the drug with all move the result.

The lifestyle piece cuts both ways. In SURMOUNT-3, participants first lost weight through an intensive lifestyle program and then added tirzepatide — and lost substantially more on top, showing the drug stacks additional effect onto diet-and-activity changes rather than replacing them⁵. Tirzepatide is a powerful tool, but the trials that produced these numbers all included lifestyle support; the drug isn't doing the work in a vacuum.

The part the "after" photo never shows: maintenance and regain

Here's the most important honesty in this whole topic. The weight loss depends on staying on the drug. SURMOUNT-4 is the trial built to test exactly this: everyone first took tirzepatide for 36 weeks (losing about 21% on average), then half were switched to placebo. The group that kept taking it lost a further ~5.5%, while the group that stopped regained about 14% of their body weight back over the next year⁶. Nearly 90% of those who continued kept at least four-fifths of their loss; only about 17% of those who stopped did⁶.

That reframes "results" entirely. The numbers in the table above are while-on-treatment figures. They are not a one-time transformation you bank and keep effortlessly — chronic weight management means the effect persists as long as treatment does, and substantially reverses when it ends. Whether and how to step down to a lower long-term dose after reaching your goal is a clinician-led decision; we cover the framing in our tirzepatide dosage chart and the broader evidence in the tirzepatide evidence guide.

How Zepbound's results compare

Because people often ask whether a different drug would do more: in SURMOUNT-5, a head-to-head trial, tirzepatide produced greater average weight loss than semaglutide (the molecule in Wegovy/Ozempic)⁷. That's consistent with the dose-response pattern and the network meta-analyses⁴. We unpack that comparison in tirzepatide vs semaglutide, and how it stacks up against the older daily GLP-1 drug in Saxenda vs Zepbound. It's worth noting tirzepatide's gastrointestinal side effects are also dose-dependent and concentrated during titration, so "more loss" and "more to tolerate" travel together⁸ — see the full Zepbound side effects breakdown.

The honest bottom line

In controlled trials, Zepbound produced average weight loss of roughly 15% at 5 mg, 19.5% at 10 mg, and 21% at 15 mg over about 72 weeks in adults with obesity and no diabetes — a large, clinically meaningful result for most people, but a range, not a promised number, and lower in people with diabetes¹³. It works on a timeline of months and quarters, not weeks, because the dose is climbed slowly and the biggest losses accrue over a year or more². And the results hold only while treatment continues — stopping leads to substantial regain⁶. The realistic "before and after," then, isn't a photo; it's a months-long curve that depends on your dose, your starting point, your adherence, and the lifestyle changes alongside it. For how this trial picture lines up with what people actually say, see Zepbound reviews: what real users (and the trials) report. To weigh how to access brand Zepbound and what it costs, start with our best tirzepatide overview.